Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib versus other second-generation ALK TKIs in ALK-positive non-small cell lung cancer
2019-001828-36Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Sep 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brigatinib, alectinib and ceritinib in non-small cell lung cancer (NSCLC) and ALK-positive non-small cell lung cancer (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Progression-free survival in first-line treatment. Started Sep 2019; status: active.
02
Drugs
brigatinibalectinibceritinib
03
Conditions
non-small cell lung cancer (NSCLC)ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on 2019-001828-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001828-36.